Evolution and treatment.
During the admission, 67/151 (44%) patients required oxygen therapy, during a median of 4 days (IQR 2–28). Regarding respiratory support, 15/151 (10%) required high-flow ventilation (HFV) or continuous positive airway pressure (CPAP); 11/151 (7%) required intubation and mechanical ventilation (MV) during a median of 5 days (IQR 2–16), and 2/151 (1%) required extracorporeal membrane oxygenation therapy.
Overall, 112/151 (74%) patients received antibiotics, mainly, azithromycin (55/112, 49%), ceftriaxone (27/112, 24%), ampicillin (5/112, 4%) or meropenem (6/112, 5%). Antivirals were administered to 67/151 (44%) patients; the most common were remdesivir (12/67, 18%) and lopinavir/ritonavir (10/67, 15%). Other treatments used were hydroxychloroquine in 52/151 (34%) patients, and immunoglobulins (3/151, 2%) or glucocorticoids (30/151, 20%).